Program
Chickenpox Vaccine
Also written as “Varicella Vaccine”, “Investigational live attenuated varicella vaccine” and “Zoster Vaccine, Live”.
Its studies are mostly in Chickenpox · Herpes Zoster · Meningococcal Infections · Measles · Streptococcal Infections, led by 6 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Merck | 210 open or running | phase 4since Feb 7, 2007 | Apr 22, 2005 | none ahead |
| Sinovac Biotech | 124 open or running | phase 4since Oct 14, 2021 | Nov 14, 2016 | Dec 2028phase 4 · NCT06484686 |
| GlaxoSmithKline | 60 open or running | phase 3since Sep 13, 2005 | Sep 13, 2005 | none ahead |
| Sinopharm | 22 open or running | phase 3since Dec 20, 2022 | Dec 20, 2022 | none ahead |
| Changchun Changsheng Life Science and Technology | 10 open or running | phase 4since Oct 24, 2013 | Oct 24, 2013 | none ahead |
| GC Biopharma | 10 open or running | phase 3since Nov 28, 2017 | Nov 28, 2017 | none ahead |
Also a collaborator on its studies: beijing-institute-of-biological-products-co-ltd.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 27 studies since Apr 22, 2005.
- Nov 14, 2016Sinovac Biotech's first study: phase 1 study in ChickenpoxNew to Sinovac BiotechSinovac Biotech · NCT02965404 · 270 enrolled · China
- Nov 28, 2016Phase 3 study in ChickenpoxSinovac Biotech · NCT02981836 · 5,997 enrolled · China
- Nov 28, 2017GC Biopharma's first study: phase 3 study in Healthy ChildrenNew to GC BiopharmaGC Biopharma · NCT03375502 · 814 enrolled · Korea, Republic of
- Feb 14, 2019Phase 3 study in ChickenpoxMerck · NCT03843632 · 150 enrolled · Russian Federation
- Oct 14, 2021Phase 4 study in ChickenpoxSinovac Biotech · NCT05095701 · 703 planned · China
- Nov 22, 2021Phase 3 study in ChickenpoxSinovac Biotech · NCT05150392 · 1,193 enrolled · China
- Jul 12, 20222 phase 4 studies in ChickenpoxSinovac Biotech · NCT05470855, NCT05460429
- Dec 20, 2022Sinopharm's first study: phase 3 study in ChickenpoxNew to SinopharmSinopharm · NCT05669625 · 12,440 enrolled · China
- Apr 20, 2023Phase 3 study in ChickenpoxSinopharm · NCT05839301 · 1,200 enrolled · China
- Mar 6, 2024Phase 3 study in ChickenpoxSinovac Biotech · NCT06314724 · 642 enrolled · Philippines
- Jun 26, 2024Phase 4 study in ChickenpoxSinovac Biotech · NCT06484686 · 414 planned · China
- Mar 2, 2025Phase 4 study in ChickenpoxSinovac Biotech · NCT06891872 · 720 planned · China
- May 15, 20252 phase 4 studiesSinovac Biotech · NCT06987942, NCT06994052
- Mar 11, 2026Phase 3 study in ChickenpoxSinovac Biotech · NCT07473427 · 300 planned · Vietnam
Ahead
- Dec 2028Primary completion: phase 4 study in ChickenpoxSinovac Biotech · NCT06484686
TargetBeta
A vaccine: it acts on a pathogen, not a human gene.
Studies
All 43 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07473427Chickenpox · Vietnam | 3 | Not yet recruiting | Sinovac Biotech | Aug 1, 2026 | 300 |
| NCT06994052VZV · China | 4 | Completed | Sinovac Biotech | Nov 30, 2024 | 412 |
| NCT06987942Chickenpox · China | 4 | Completed | Sinovac Biotech | Nov 15, 2024 | 899 |
| NCT06891872Chickenpox · China | 4 | Not yet recruiting | Sinovac Biotech | Dec 2025 | 720 |
| NCT06484686Chickenpox · China | 4 | By invitation | Sinovac Biotech | Dec 2028 | 414 |
| NCT06314724Chickenpox · Philippines | 3 | Completed | Sinovac Biotech | Sep 6, 2024 | 642 |
| NCT05839301Chickenpox · China | 3 | Active, not recruiting | Sinopharm | Jul 30, 2023 | 1,200 |
| NCT05669625Chickenpox · China | 3 | Active, not recruiting | Sinopharm | Apr 14, 2024 | 12,440 |
| NCT05470855Chickenpox · China | 4 | UNKNOWN | Sinovac Biotech | Nov 30, 2022 | 45,400 |
| NCT05460429Chickenpox · China | 4 | UNKNOWN | Sinovac Biotech | Mar 15, 2023 | 37,920 |
| NCT05150392Chickenpox · China | 3 | Completed | Sinovac Biotech | Aug 11, 2018 | 1,193 |
| NCT05095701Chickenpox · China | 4 | By invitation | Sinovac Biotech | Dec 19, 2021 | 703 |
| NCT03843632Chickenpox · Russian Federation | 3 | Completed | Merck | Jun 19, 2020 | 150 |
| NCT03375502Healthy Children · Korea, Republic of | 3 | Completed | GC Biopharma | Jan 29, 2019 | 814 |
| NCT02981836Chickenpox · China | 3 | Completed | Sinovac Biotech | Jun 2017 | 5,997 |
| NCT02965404Chickenpox · China | 1 | Completed | Sinovac Biotech | May 2016 | 270 |
| NCT02519855Herpes Zoster | 3 | Completed | Merck | Jan 26, 2016 | 882 |
| NCT01982409Chickenpox · China | 4 | UNKNOWN | Changchun Changsheng Life Science and Technology | Jan 2018 | 350 |
| NCT01556451Herpes Zoster | 4 | Completed | Merck | Oct 2012 | 180 |
| NCT01527370Herpes Zoster | 3 | Completed | Merck | Apr 9, 2013 | 250 |
| NCT01505647Herpes Zoster | 3 | Completed | Merck | Jul 2012 | 498 |
| NCT01391546Herpes Zoster | 3 | Completed | Merck | Oct 15, 2012 | 354 |
| NCT01385566Herpes Zoster | 1 | Completed | Merck | May 2013 | 223 |
| NCT01245751Herpes Zoster | 3 | Completed | Merck | Jul 2012 | 600 |
| NCT00822237Chickenpox | 3 | Completed | Merck | Oct 2009 | 598 |
| NCT00681031Herpes Zoster | 4 | Completed | Merck | Jun 25, 2008 | 96 |
| NCT00624819Streptococcal Infections · Poland | 3 | Completed | GlaxoSmithKline | Jun 2, 2008 | 524 |
| NCT00568334Chickenpox · Czechia, Hungary | 2 | Completed | GlaxoSmithKline | Mar 18, 2008 | 244 |
| NCT00561080Prevention of : Herpes-Zoster | 3 | Completed | Merck | Jun 3, 2009 | 759 |
| NCT00550745Herpes Zoster | 4 | Completed | Merck | Jan 2009 | 11,999 |
| NCT00546819Herpes Zoster | 2 | Completed | Merck | Aug 2010 | 309 |
| NCT00534248Herpes Zoster | 3 | Completed | Merck | Jan 2010 | 22,439 |
| NCT00496327Chickenpox | 3 | Completed | Merck | Oct 6, 2005 | 100 |
| NCT00444860Varicella Virus Infection | 3 | Completed | Merck | May 2007 | 150 |
| NCT00432731Chickenpox · France, Italy | 4 | Completed | Merck | Sep 2005 | 500 |
| NCT00432523Measles · France, Germany | 3 | Completed | Merck | Sep 5, 2005 | 752 |
| NCT00406211Rubella · Austria, Germany | 3 | Completed | GlaxoSmithKline | Dec 2004 | 398 |
| NCT00322231Herpes Zoster | 3 | Completed | Merck | Jul 2007 | 101 |
| NCT00289783Haemophilus Infections · United States, Australia, Mexico | 3 | Completed | GlaxoSmithKline | Aug 27, 2007 | 4,441 |
| NCT00231816Herpes Zoster | 3 | Completed | Merck | Mar 2006 | 763 |
| NCT00226499Chickenpox · Czechia, Greece, Italy and more | 3 | Completed | GlaxoSmithKline | Oct 12, 2006 | 5,803 |
| NCT00197015Hepatitis A · United States | 3 | Completed | GlaxoSmithKline | Jun 9, 2009 | 1,474 |
| NCT00109122Herpes Zoster | 2 | Completed | Merck | Feb 2003 | 180 |
How it is read
Names in the registry
- “Varicella Vaccine”, 4 entries
- “Investigational live attenuated varicella vaccine”, 4 entries
- “Zoster Vaccine, Live”, 3 entries
- “Varicella Virus Vaccine Live”, 2 entries
- “Live Attenuated Varicella Vaccine”, 2 entries
Conditions, from the studies’ own filings
- Chickenpox, 24 studies
- Herpes Zoster, 15 studies
- Meningococcal Infections, 1 study
- Measles, 1 study
- Streptococcal Infections, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.